15.40MMarket Cap-558P/E (TTM)
3.4100High3.0600Low126.30KVolume3.3900Open3.4100Pre Close405.27KTurnover2.58%Turnover RatioLossP/E (Static)5.02MShares44.500052wk High0.81P/B15.01MFloat Cap3.060052wk Low--Dividend TTM4.89MShs Float197.5000Historical High--Div YieldTTM10.26%Amplitude3.0600Historical Low3.2080Avg Price1Lot Size
Matinas BioPharma Stock Forum
📊⚡️📊
Matinas BioPharma Reports Successful Treatment of Patient With Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program
3 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of L...
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel
Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-doce...
No comment yet